pharma news today glp-1 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Glucagon-like Peptide 1 (GLP-1) Analogues

Endocrinology 119 (4), 14671475

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

Glucagon also increases energy expenditure and brown adipose tissue (BAT) activity in mice [46], actions that are partially diminished in Fgf21 / mice [46]

#DiabetesResearch Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies - Diabetologia link.springer.com To view or add a comment, sign in More Relevant Posts Major milestone in diabetes-cardiovascular therapeutics The Rybelsus (oral semaglutide) tablets from Novo Nordisk have just received FDA approval to reduce the risk of major adverse cardiovascular events (MACE) including heart attack, stroke, or cardiovascular death in adults living with type 2 diabetes at elevated cardiovascular risk

If you take insulin or sulfonylureas alongside your GLP-1 medication, discuss with your healthcare team whether these doses need adjustment as your eating patterns change, to avoid low blood glucose levels that can worsen fatigue